Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Carducci

Showing results (61-70 of 322) with videos related to

Pageof 33
Sort By:
The Prostate|May 5, 2007
Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivoShabana Shabbeer, Madeleine S Q Kortenhorst, Sushant Kachhap, et al.
The Prostate|August 9, 2017
Risk factors for metastatic prostate cancer: A sentinel event case seriesChanning J Paller, Alexander P Cole, Alan W Partin, et al.
Cancer|March 29, 2002
Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinomaVictoria J Sinibaldi, Michael A Carducci, Sandra Moore-Cooper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2022
Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate CancerRahul Aggarwal, Alexander N Starodub, Brian D Koh, et al.
JCO Oncology Practice|April 4, 2022
Oncologist Peer Comparisons as a Behavioral Science Strategy to Improve Hospice UtilizationRamy Sedhom, Amanda L Blackford, Arjun Gupta, et al.
Cancer|October 1, 2011
Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trialsEmmanuel S Antonarakis, Marianna L Zahurak, Jianqing Lin, et al.
Urologic Oncology|December 8, 2009
Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancerJianqing Lin, Victoria J Sinibaldi, Michael A Carducci, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|November 24, 2004
Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatographyMing Zhao, Michelle A Rudek, Ping He, et al.
Clinical Genitourinary Cancer|August 15, 2015
Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800)Michael A Carducci, Judith Manola, Suresh G Nair, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|April 12, 2016
Corrigendum to "Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography" [J. Chromatogr. B 813(1) (2004) 81-88]Ming Zhao, Michelle A Rudek, Ping He, et al.
Pageof 33

Showing results (61-70 of 322) with videos related to

Sort By:
Pageof 33
The Prostate|May 5, 2007
Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivoShabana Shabbeer, Madeleine S Q Kortenhorst, Sushant Kachhap, et al.
The Prostate|August 9, 2017
Risk factors for metastatic prostate cancer: A sentinel event case seriesChanning J Paller, Alexander P Cole, Alan W Partin, et al.
Cancer|March 29, 2002
Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinomaVictoria J Sinibaldi, Michael A Carducci, Sandra Moore-Cooper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2022
Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate CancerRahul Aggarwal, Alexander N Starodub, Brian D Koh, et al.
JCO Oncology Practice|April 4, 2022
Oncologist Peer Comparisons as a Behavioral Science Strategy to Improve Hospice UtilizationRamy Sedhom, Amanda L Blackford, Arjun Gupta, et al.
Cancer|October 1, 2011
Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trialsEmmanuel S Antonarakis, Marianna L Zahurak, Jianqing Lin, et al.
Urologic Oncology|December 8, 2009
Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancerJianqing Lin, Victoria J Sinibaldi, Michael A Carducci, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|November 24, 2004
Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatographyMing Zhao, Michelle A Rudek, Ping He, et al.
Clinical Genitourinary Cancer|August 15, 2015
Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800)Michael A Carducci, Judith Manola, Suresh G Nair, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|April 12, 2016
Corrigendum to "Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography" [J. Chromatogr. B 813(1) (2004) 81-88]Ming Zhao, Michelle A Rudek, Ping He, et al.
Pageof 33